ORPEF Quote, Financials, Valuation and Earnings

DBV Technologies SA has a net margin of -- compared to Emeis SA's net margin of --. Emeis SA's return on equity of 221.67% beat DBV Technologies SA's return on equity of -280.59%.

Emeis SA has a consensus price target of --, signalling downside risk potential of --. On the other hand DBV Technologies SA has an analysts' consensus of $20.63 which suggests that it could grow by 20.24%. Given that DBV Technologies SA has higher upside potential than Emeis SA, analysts believe DBV Technologies SA is more attractive than Emeis SA.

Emeis SA has a beta of 632.999, which suggesting that the stock is 63199.944% more volatile than S&P 500. In comparison DBV Technologies SA has a beta of -1.102, suggesting its less volatile than the S&P 500 by 210.179%.

Emeis SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emeis SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Emeis SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Emeis SA's net income of -- is lower than DBV Technologies SA's net income of -$33M. Notably, Emeis SA's price-to-earnings ratio is 1.15x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emeis SA is 0.17x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Innate Pharma SA has a net margin of -- compared to Emeis SA's net margin of --. Emeis SA's return on equity of 221.67% beat Innate Pharma SA's return on equity of -72.79%.

Emeis SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Innate Pharma SA has an analysts' consensus of $5.15 which suggests that it could grow by 172.27%. Given that Innate Pharma SA has higher upside potential than Emeis SA, analysts believe Innate Pharma SA is more attractive than Emeis SA.

Emeis SA has a beta of 632.999, which suggesting that the stock is 63199.944% more volatile than S&P 500. In comparison Innate Pharma SA has a beta of -0.081, suggesting its less volatile than the S&P 500 by 108.148%.

Emeis SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innate Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emeis SA pays -- of its earnings as a dividend. Innate Pharma SA pays out -- of its earnings as a dividend.

Emeis SA quarterly revenues are --, which are smaller than Innate Pharma SA quarterly revenues of --. Emeis SA's net income of -- is lower than Innate Pharma SA's net income of --. Notably, Emeis SA's price-to-earnings ratio is 1.15x while Innate Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emeis SA is 0.17x versus 24.45x for Innate Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.

Inventiva SA has a net margin of -- compared to Emeis SA's net margin of --. Emeis SA's return on equity of 221.67% beat Inventiva SA's return on equity of --.

Emeis SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Inventiva SA has an analysts' consensus of $15.33 which suggests that it could grow by 259.94%. Given that Inventiva SA has higher upside potential than Emeis SA, analysts believe Inventiva SA is more attractive than Emeis SA.

Emeis SA has a beta of 632.999, which suggesting that the stock is 63199.944% more volatile than S&P 500. In comparison Inventiva SA has a beta of 0.746, suggesting its less volatile than the S&P 500 by 25.433%.

Emeis SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inventiva SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emeis SA pays -- of its earnings as a dividend. Inventiva SA pays out -- of its earnings as a dividend.

Emeis SA quarterly revenues are --, which are smaller than Inventiva SA quarterly revenues of --. Emeis SA's net income of -- is lower than Inventiva SA's net income of --. Notably, Emeis SA's price-to-earnings ratio is 1.15x while Inventiva SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emeis SA is 0.17x versus 24.80x for Inventiva SA. Usually stocks with elevated PS ratios are considered overvalued.

Nanobiotix SA has a net margin of -- compared to Emeis SA's net margin of --. Emeis SA's return on equity of 221.67% beat Nanobiotix SA's return on equity of --.

Emeis SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Nanobiotix SA has an analysts' consensus of $14.75 which suggests that it could fall by -30.65%. Given that Nanobiotix SA has higher upside potential than Emeis SA, analysts believe Nanobiotix SA is more attractive than Emeis SA.

Emeis SA has a beta of 632.999, which suggesting that the stock is 63199.944% more volatile than S&P 500. In comparison Nanobiotix SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Emeis SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanobiotix SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emeis SA pays -- of its earnings as a dividend. Nanobiotix SA pays out -- of its earnings as a dividend.

Emeis SA quarterly revenues are --, which are smaller than Nanobiotix SA quarterly revenues of --. Emeis SA's net income of -- is lower than Nanobiotix SA's net income of --. Notably, Emeis SA's price-to-earnings ratio is 1.15x while Nanobiotix SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emeis SA is 0.17x versus 29.67x for Nanobiotix SA. Usually stocks with elevated PS ratios are considered overvalued.